ABSTRACT
INTRODUCTION
Until the recent introduction of non-invasive prenatal testing (NIPT), combined first-trimester serum screening (CFTS) was the predominant form of screening for trisomy 21 (T21) in many countries. As NIPT spread globally following its initial launch in China and the USA in 2011, considerable debate has ensued on the most appropriate method of its integration into clinical practice and local population-based screening programs [1] [2] [3] . NIPT was initially promoted as a secondary screening test for pregnancies already known to be at increased risk of T21 based on conventional screening tests or maternal age 4 , but it is now considered as an acceptable primary screening test for women of any background risk 5 . There are ongoing concerns, however, that replacing CFTS with NIPT for T21 screening will lead to a decline in the 11-13-week nuchal translucency (NT) ultrasound and resultant missed opportunities for early detection of fetal structural malformations 6 . There are additional concerns that the use of NIPT as a secondary screening test, i.e. the so-called 'contingent' model 7, 8 , may lead to a reduction in the detection of atypical chromosome abnormalities identified previously through diagnostic testing after a result of high risk on CFTS 9, 10 . One population-based study has reported an increased risk of atypical chromosome abnormalities in women with low maternal serum markers (pregnancy-associated plasma protein-A (PAPP-A) or beta-human chorionic gonadotropin (β-hCG) < 0.2 multiples of the median (MoM)), independent of CFTS risk result 11 . However, the corresponding CFTS results were not reported for the group with very low serum analyte levels, making it unclear if they would have been offered diagnostic testing based on CFTS result alone. The role of ultrasound anomalies in the detection of atypical abnormalities was also not examined. Although there have been numerous studies reporting on the overall decline in invasive testing since the introduction of NIPT [12] [13] [14] [15] , there is a lack of population-based data on the relationship between numerical CFTS risk result and uptake of diagnostic testing in the pre-and post-NIPT eras. If clinicians are providing the recommended pretest counseling on the limitations of NIPT 16 , it is possible that women at the highest risk of atypical abnormalities (e.g. those with CFTS risk result > 1 in 50) would continue to have high rates of diagnostic testing.
In view of this rapidly evolving prenatal screening environment and the debate regarding thresholds for contingent models of NIPT, we performed a population-based study to analyze the uptake of invasive diagnostic testing after CFTS according to numerical risk result, and to analyze the prevalence and ascertainment of atypical chromosome abnormalities and pathogenic copy number variations (CNVs) according to CFTS risk result and individual serum marker MoM.
METHODS
In the Australian state of Victoria, there are approximately 73 000 births per annum (median maternal age, 31.5 years; average fertility rate, 1.7 births per woman; and average weekly disposable household income AUD 998; http://www.abs.gov.au).
Voluntary screening for fetal chromosome and structural abnormalities in Victoria is universally available 17 . Government rebates are available for CFTS, secondtrimester serum screening (STSS) and mid-trimester morphology ultrasound with variable out-of-pocket cost to the patient (typically < AUD 200). CFTS, in addition to ultrasound measurement of NT, includes serum measurement of PAPP-A and free β-hCG. STSS is conducted between 14 and 20 weeks' gestation as a quadruple panel including α-fetoprotein, unconjugated estriol, free β-hCG and dimeric inhibin A. Invasive testing is fully government-funded in the public sector to women at increased risk and partially funded if performed in the private sector. There is no additional charge for chromosomal microarray analysis (CMA) in the public sector. NIPT is not currently government-funded and the total cost (approximately AUD 500) is borne by the patient. Data on all women in Victoria undergoing invasive prenatal diagnostic testing (amniocentesis or chorionic villus sampling) prior to 25 weeks' gestation from January 2014 to December 2015 were obtained from the Victorian Prenatal Diagnosis Database (see Acknowledgments for contributors). The gestational age limit of 25 weeks was designated to capture invasive testing performed after routine first-and second-trimester screening 13 . The screening and diagnostic datasets were probabilistically linked using LinkageWiz™ (http://www.linkagewiz.net/), using family name, date of birth and postcode as individual identifiers. Potential data matches were manually examined and confirmed or rejected using the clerical review tool in LinkageWiz. For records without complete identifiers, manual linkage was performed in Microsoft Excel, using a combination of name, maternal age and dates of screening and diagnostic testing.
2014-2015 data sources
In our population, women with a CFTS T21 risk of 1 in 300 or higher are reported as 'high risk' and are offered genetic counseling. Clinical pathways for high risk women include secondary screening with NIPT at their own cost, invasive diagnostic testing with G-banding karyotyping or CMA, or no further testing. Women with a CFTS T21 risk of less than 1 in 300 may also opt for NIPT or diagnostic testing, according to individual preference.
Analysis
Following data linkage between the screening and diagnostic datasets, CFTS results were coded as high risk (≥ 1 in 300 for T21, ≥ 1 in 175 for T18 and ≥ 1 in 100 for T13), according to standard clinical reporting practice, low risk or unknown risk. Women with unknown risk were those who had undergone serum screening but had incorrect dates, or who did not have a NT measurement supplied for risk calculation. These women were excluded from the CFTS analysis, but included in the serum analyte analysis. STSS results were coded as high risk if the risk of T21 was ≥ 1 in 250, the risk of T18 was ≥ 1 in 200 or the risk of neural tube defect was increased due to alpha-fetoprotein level > 2.5 MoM 17 . Descriptive analysis was performed in Stata version 14 (StataCorp, College Station, TX, USA).
Diagnostic karyotyping results were explored according to CFTS T21 risk, PAPP-A MoM and free β-hCG MoM subcategories. Normal karyotype included 46XX, 46XY and balanced translocations. Major chromosome abnormalities included T21, T18, T13, other autosomal trisomies, triploidy, sex chromosome anomalies, pathogenic CNVs, unbalanced translocations and level III mosaicism.
Pathogenic CNVs included deletions or duplications in a region associated with an abnormal phenotype 18 . Atypical abnormalities were defined as major abnormalities not detectable on standard five-chromosome NIPT, that is, excluding T21, T18, T13, monosomy X and sex chromosome trisomies. CNVs of uncertain or unknown significance were excluded.
Data for the historical comparison group spanning the period 2002-2004 were obtained from a published study from the Victorian Prenatal Diagnosis Database 19 . No additional data analysis was performed on this cohort. Of the women who underwent first-trimester serum screening, 2.8% (2901/103 319) did not have a CFTS risk result reported due to missing NT data or ultrasound examination performed outside of the specified gestational ages. These women were excluded from the CFTS analysis, but included in the analysis of serum analytes. Of the 100 418 women who had a CFTS result issued, 3.2% (3199) were high risk and 90.4% (90 787) low risk for T21. Overall, 2.2% (2226) of women who had CFTS underwent invasive diagnostic testing. 
RESULTS

Atypical chromosome abnormalities: 2014-2015
In the total 2014-2015 CFTS cohort, the prevalence of chromosome abnormalities was 0.4%; 25.1% of these were atypical chromosome abnormalities not detectable on NIPT (n = 102). The risk of chromosome abnormality stratified by T21 risk result on CFTS is presented in Tables 2 and 3 . The prevalence of atypical abnormality increased with CFTS risk result, from 1.4% in women with a CFTS T21 risk of ≥ 1 in 300 to 4.6% for women with a risk of > 1 in 10 ( Table 3) . Over 40% (43/102) of atypical abnormalities were found in the low-risk group (risk ≤ 1 in 1000) ( Table 2 ). The largest group of atypical abnormalities were pathogenic CNVs (n = 47), including 22 deletions or duplications of the 22q11.2 region. The prevalence of atypical chromosome abnormalities among women with serum PAPP-A or free β-hCG levels < 0.2 MoM was 6.9% (20/291) and 5.2% (10/192), respectively (Table 4) . We examined the corresponding individual CFTS risk results for women with serum markers < 0.2 MoM and found that 49.2% (58/118) of women with a PAPP-A < 0.2 MoM had a CFTS risk of T21 of < 1 in 100. Within this group, 39.7% (23/58) had an abnormal karyotype: T21 (n = 4), T18 (n = 7), T13 and 11 atypical abnormalities (triploidy (n = 9), trisomy 16 and level III mosaicism). Among women with a free β-hCG result of < 0.2 MoM, 88.5% (33/41) had a CFTS T21 risk < 1 in 100, 54.5% (18/33) of which had a pregnancy with an abnormal karyotype. These included T18 (n = 10) and eight atypical abnormalities (triploidy (n = 6), pathogenic CNV and trisomy 9).
The primary indications for invasive diagnostic testing among the 102 pregnancies with an atypical chromosome abnormality were as follows: ultrasound abnormality (n = 38), CFTS T21 risk of > 1 in 100 (n = 30), CFTS T21 risk 1 in 100-300 (n = 5), CFTS T18 risk > 1 in 150 (n = 14), and result of high risk on NIPT (n = 3) ( Table S1 ). The remainder of the group had invasive diagnostic testing performed for other indications, including advanced maternal age, family history of aneuploidy or multiple indications. A substantial proportion of ultrasound-indicated tests were performed prior to 18 weeks (44.7%; 17/38), representing the early detection of structural abnormalities prior to the routine mid-trimester morphology scan. Ten women had an ultrasound abnormality along with another indication for testing. When combined with the primary ultrasound indication group, ultrasound abnormality was an indication for invasive diagnostic testing in 47% (n = 48) of pregnancies with atypical abnormalities.
DISCUSSION
In this period of rapid change in prenatal screening, there has been increasing scrutiny of the contribution of conventional screening to aneuploidy detection over that provided by standard five-chromosome NIPT. Ours is one of the few large population-based datasets that has been able to report on the incremental value of individual serum markers and ultrasound abnormalities on the detection of atypical abnormalities after CFTS. We confirmed an increase in risk of atypical chromosome abnormality with increasing T21 risk on CFTS (from 1.4% for those with a risk of ≥ 1 in 300 to 4.6% for those with a risk of > 1 in 10). In concordance with a previously reported Danish national study, we observed that a substantial proportion of women with analyte levels < 0.2 MoM were at increased risk of atypical abnormalities (6.9% for PAPP-A and 5.2% for free β-hCG) 11 . Importantly, almost half of these women had a CFTS risk result of less than 1 in 100, suggesting that individual serum markers should be considered independently in a decision pathway in which NIPT is to be offered after CFTS. In our population, 42.2% of pregnancies with an atypical chromosome abnormality had a CFTS risk result ≤ 1 in 1000 and thus would not be offered diagnostic testing or NIPT within most contingent models.
Our results also show that ultrasound remains an important method for the detection of atypical chromosome abnormalities, contributing to detection of almost one-half of cases (47%). Furthermore, 17 women had an atypical chromosome abnormality detected prior to 18 weeks' gestation due to ultrasound abnormality alone, highlighting the continued importance of high-quality first-and second-trimester ultrasound for the detection of chromosome abnormalities.
Based on our data, 90.2% of atypical abnormalities could be detected by offering diagnostic testing to women with high risk for T21 (> 1 in 100) on CFTS, serum analytes < 0.2 MoM or ultrasound abnormality. The other tests that revealed atypical abnormalities were performed for pregnancies with advanced maternal age, which remains a relatively minor but enduring indication for invasive testing in our population. As there is no specific screening test for atypical abnormalities, the 90.2% detection rate using these suggested risk groups seems a reasonable approach, short of routinely offering invasive diagnostic testing to all women, which has been proposed as a warranted approach by some opinion leaders 20 . Other developments in the expansion of NIPT beyond the common autosomal trisomies and sex chromosome abnormalities have the potential to reduce further missed diagnoses of atypical abnormality, including microdeletions 21, 22 , rare autosomal trisomies 23 and subchromosomal abnormalities 24 . However, due to the paucity of robust clinical validity studies and the potential to inflate the screen-positive rate of NIPT, routine screening for these conditions using NIPT is not currently recommended by any professional society (Society for Maternal Fetal Medicine, American College of Obstetrics and Gynecology, American Congress of Human Genetics and Genomics, Royal Australian and New Zealand College of Obstetricians and Gynaecologists) 5, 25 . Our historical comparison of invasive testing rates demonstrates a systematic shift away from invasive testing across all CFTS risk result categories over the past decade, including risk of > 1 in 50 that traditionally has a high rate of diagnostic testing. Despite the decline in diagnostic testing uptake, the diagnostic yield has increased markedly due to a number of factors. Firstly, incorporation of visualization of the nasal bone into the CFTS algorithm reduces the false-positive rate of CFTS 13 . Secondly, the increasing use of NIPT as a secondary screening test after a high-risk CFTS result further reduces false positives. Finally, those women that have diagnostic testing are now likely to have fetal chromosome analysis using CMA. CMA made up 75% of all prenatal tests in Victoria in 2014-2015 13 and at least 50% of subspecialists now order CMA routinely for all diagnostic testing 26 . The prevalence of pathogenic CNVs in our total diagnostic cohort of 2.1% (47/2226) is similar to the 2.2% reported by Vogel et al. in their population-based study on routine CMA after a high-risk result on CFTS 27 . Our study was limited by the lack of access to NIPT data, including the number of women using NIPT and the use of NIPT for primary or secondary screening. We could only speculate that the decline in diagnostic testing was, in part, due to the introduction of NIPT. The changing pattern in uptake of diagnostic testing may also be due to difference in the profile of women now accessing CFTS. In 2002-2004, CFTS was in its introduction phase, with < 50% population uptake and, hence, a selection bias in the women accessing CFTS may have existed (e.g. metropolitan residence, higher socioeconomic status, older). Now, with CFTS utilized by over 70% of the population, the preferences for diagnostic testing may have shifted with demographic characteristics, independent of other developments in prenatal screening such as NIPT.
This study was also dependent on the information provided by the clinical referral center and the participating laboratories regarding the indications for testing, as we did not have direct access to individual ultrasound reports or hospital records. It is possible that relevant details regarding the indications for testing were not documented, particularly those with ultrasound abnormalities or multiple indications.
Our analysis of atypical chromosome abnormalities is limited by the absence of information on pregnancy outcome. Access to such data would have allowed determination of pregnancy complications and birth outcome for the various types of chromosome abnormalities, and ascertainment of rates of 'missed' atypical abnormalities that were subsequently diagnosed at birth. This study was also confined to the cohort that underwent CFTS and did not include atypical abnormalities found in women who underwent other forms of screening or no screening. This was in order to simplify the modeling for proposed screening pathways including universal CFTS.
In conclusion, this study demonstrates that the detection of atypical chromosome abnormalities within a large CFTS cohort is predominantly via fetal structural abnormalities and, to a lesser extent, T21 risk on CFTS. A clinical pathway that offers diagnostic testing for women with T21 risk > 1 in 100, individual serum analytes < 0.2 MoM or ultrasound abnormality would detect the vast majority (> 90%) of atypical chromosome abnormalities not detected by NIPT in our population.
